Metsera, Inc., a biopharmaceutical company focused on obesity and metabolic diseases, has announced the advancement of its MET-097i program into a Phase II clinical trial. This decision follows positive topline results from a Phase I/II trial, supported by Altasciences, demonstrating a significant reduction in body weight. MET-097i is an ultra-long-acting injectable, fully biased GLP-1 receptor agonist.
Phase I/II Trial Results
The Phase I/II trial of MET-097i, conducted at Altasciences’ facility, showed a 7.5% reduction in body weight from baseline at day 36, one week after the final dose. The compound also exhibited a 380-hour half-life, suggesting the potential for once-monthly administration. These results were reported in September, paving the way for the initiation of a randomized, 16-week Phase II trial.
Broader Development Program
Beyond MET-097i, Altasciences has supported Metsera with its Proactive Drug Development solution, including nonclinical, bioanalysis, CRO, and program management services for several therapeutic candidates. This includes nonclinical work for MET-233i, an ultra-long-acting injectable amylin analog, and MET-002, an oral GLP-1 receptor agonist peptide. These efforts have enabled Metsera to initiate clinical trials for both programs this year.
Expert Commentary
"Congratulations to Metsera on reaching this significant milestone in the development of MET-097i," said Ingrid Holmes, Vice President of Global Clinical Operations at Altasciences. "Metsera is a highly valued partner of Altasciences, and we are proud to have contributed to this program aimed at helping individuals struggling with obesity-related illnesses."
Obesity and Unmet Needs
Obesity affects millions globally and is a major contributor to serious health risks, including type 2 diabetes, heart disease, and certain cancers. New treatments like MET-097i could provide valuable options for those affected by this complex condition.
